LTX-315 Completed Phase 1 Trials for Carcinoma NOS

IndicationsStatusPurposePhase
CompletedNot Available1
clinicaltrials.gov IdentifierTitleDrugs
NCT01223209A Study, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma